ArticleMolecules (Basel, Switzerland)2019
Potent in Vitro α-Glucosidase Inhibition of Secondary Metabolites Derived from
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 23 citations in OpenAlex.
- Ethnopharmacological insights into type 2 diabetes management by traditional Moroccan herbal teas: HPLC-MS characterization of phenolic compounds and their related antioxidant and enzyme inhibitory activities.BMC complementary medicine and therapies · 2026Article
- Isolation, structural elucidation, and integrated biological and computational evaluation of antidiabetic labdane diterpenes fromRSC advances · 2025Article
- The Anti-Diabetic Effects of Medicinal Plants Belonging to the Liliaceae Family: Potential Alpha Glucosidase Inhibitors.Drug design, development and therapy · 2024Review
- Flavonoid Constituents and Alpha-Glucosidase Inhibition ofMolecules (Basel, Switzerland) · 2022Article
- Research Advances of Bioactive Sesquiterpenoids Isolated from Marine-DerivedMolecules (Basel, Switzerland) · 2022Review
- In Silico Approaches to Identify Polyphenol Compounds as α-Glucosidase and α-Amylase Inhibitors against Type-II Diabetes.Biomolecules · 2021Review
- Potential mechanism of action ofRSC advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
α-glucosidase is responsible for the hydrolysis of complex carbohydrates into simple absorbable glucose and causes postprandial hyperglycemia. α-glucosidase inhibition is thus the ideal target to prevent postprandial hyperglycemia. The present study was therefore designed to analyze the effects of various compounds isolated from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.